company background image
PRTK

Paratek PharmaceuticalsNasdaqGM:PRTK Stock Report

Market Cap

US$211.8m

7D

-9.2%

1Y

-39.2%

Updated

02 Dec, 2021

Data

Company Financials +
PRTK fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

PRTK Stock Overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.

Paratek Pharmaceuticals Competitors

Johnson & Johnson

NYSE:JNJ

US$410.5b

Pfizer

NYSE:PFE

US$301.6b

Merck

NYSE:MRK

US$189.2b

Cumberland Pharmaceuticals

NasdaqGS:CPIX

US$74.5m

Price History & Performance

Summary of all time highs, changes and price drops for Paratek Pharmaceuticals
Historical stock prices
Current Share PriceUS$4.07
52 Week HighUS$11.24
52 Week LowUS$4.03
Beta1.49
1 Month Change-21.73%
3 Month Change-26.53%
1 Year Change-39.16%
3 Year Change-43.24%
5 Year Change-69.51%
Change since IPO-74.56%

Recent News & Updates

Oct 18

The Play On Paratek Pharmaceuticals

Today, we take a quick look back at antibiotic concern Paratek Pharmaceuticals. While I am very underweight the antibiotic space due to the terrible economics there, Paratek has some unique features that make the stock one I own. An analysis and how I am positioned in Paratek Pharmaceuticals follows in the paragraphs below.

Shareholder Returns

PRTKUS PharmaceuticalsUS Market
7D-9.2%-2.1%-4.9%
1Y-39.2%12.6%17.8%

Return vs Industry: PRTK underperformed the US Pharmaceuticals industry which returned 12.6% over the past year.

Return vs Market: PRTK underperformed the US Market which returned 17.8% over the past year.

Price Volatility

Is PRTK's price volatile compared to industry and market?
PRTK volatility
PRTK Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.4%

Stable Share Price: PRTK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: PRTK's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996197Evan Lohhttps://paratekpharma.com

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd.

Paratek Pharmaceuticals Fundamentals Summary

How do Paratek Pharmaceuticals's earnings and revenue compare to its market cap?
PRTK fundamental statistics
Market CapUS$211.80m
Earnings (TTM)-US$51.84m
Revenue (TTM)US$114.39m

1.8x

P/S Ratio

-3.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PRTK income statement (TTM)
RevenueUS$114.39m
Cost of RevenueUS$46.01m
Gross ProfitUS$68.38m
ExpensesUS$120.22m
Earnings-US$51.84m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin59.78%
Net Profit Margin-45.32%
Debt/Equity Ratio-241.2%

How did PRTK perform over the long term?

See historical performance and comparison

Valuation

Is Paratek Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Paratek Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Paratek Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Paratek Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

69.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PRTK's is expected to become profitable in the next 3 years.

Revenue vs Market: PRTK's revenue (27.9% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: PRTK's revenue (27.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Paratek Pharmaceuticals performed over the past 5 years?

4.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRTK is currently unprofitable.

Growing Profit Margin: PRTK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRTK is unprofitable, but has reduced losses over the past 5 years at a rate of 4.3% per year.

Accelerating Growth: Unable to compare PRTK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: PRTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Paratek Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PRTK has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 7% each year.


Dividend

What is Paratek Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRTK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Evan Loh (62 yo)

2.42yrs

Tenure

US$1,534,611

Compensation

Dr. Evan Loh, M.D., FACC, FAHA, serves as Independent Director at Windtree Therapeutics, Inc. since February 2021. Dr. Loh has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 2...


CEO Compensation Analysis

Compensation vs Market: Evan's total compensation ($USD1.53M) is above average for companies of similar size in the US market ($USD1.13M).

Compensation vs Earnings: Evan's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: PRTK's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: PRTK's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

Paratek Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Paratek Pharmaceuticals, Inc.
  • Ticker: PRTK
  • Exchange: NasdaqGM
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$211.797m
  • Shares outstanding: 50.19m
  • Website: https://paratekpharma.com

Number of Employees


Location

  • Paratek Pharmaceuticals, Inc.
  • 75 Park Plaza
  • 4th Floor
  • Boston
  • Massachusetts
  • 2116
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/02 00:01
End of Day Share Price2021/12/01 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.